Eosinophilic complications during dupilumab therapy for type 2 diseases: a systematic review
Rhinology Journal · 01.04.2025 · 0-0
DOI: 10.4193/rhin24.528 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Rhinology Journal, online erschienen am 01.04.2025. Verfasst von M Lazzeroni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam Rhinology Team, Department of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherl…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hypereosinophilic Syndrome, Granulomatosis with Polyangiitis, Churg-Strauss Syndrome. Die Arbeit wurde bisher 11-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Dupilumab shows promising results in the management of several type 2 disorders. However, it often leads to transient, early increases in blood eosinophil count (BEC). This has led to awareness of possibly associated eosinophilic complications, such as eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Aim of the current work was to collect all eosinophilic complications reported in literature. Methodology: PubMed, Embase, Scopus, and Web of Science were systematically searched for papers reporting on eosinophilic complications of dupilumab therapy for type 2 disorders.
Results
While around one million patients are treated with dupilumab globally, we identified a total of 35 reports on 53 patients. The most common complications were EGPA: 24 patients, eosinophilic pneumonia: 15, and HES: 6. Complications developed after a median of 9 (range: 0-71) weeks and the median eosinophilic count at the moment of diagnosis was 6.38x109 cells/L (IQR 3.13- 9.08). Most complications were treated with systemic corticosteroids. Of all patients, 89% discontinued dupilumab therapy and no deceased patients were reported.
Conclusions
Reported eosinophilic complications during dupilumab therapy are extremely rare and mostly develop during the first months of treatment, challenging the need for (prolonged) BEC monitoring during dupilumab therapy. No patient patterns or predictors were identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Amsterdam Rhinology Team, Department of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;Department of Biomedical, Surgical and Dental Sciences, Universit…
- Amsterdam Rhinology Team, Department of Otorhinolaryngology and Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Zitieren
APA
Lazzeroni, M., Kemp, P., Fokkens, W. J., & Reitsma, S. (2025). Eosinophilic complications during dupilumab therapy for type 2 diseases: a systematic review. Rhinology Journal, 0(0), 0-0. https://doi.org/10.4193/rhin24.528
Vancouver
Lazzeroni M, Kemp P, Fokkens WJ, Reitsma S. Eosinophilic complications during dupilumab therapy for type 2 diseases: a systematic review. Rhinology Journal. 2025;0(0):0-0. doi:10.4193/rhin24.528
BibTeX
@article{Lazzeroni2025,
author = {Lazzeroni, M and Kemp, P and Fokkens, W J and Reitsma, S},
title = {Eosinophilic complications during dupilumab therapy for type 2 diseases: a systematic review},
journal = {Rhinology Journal},
year = {2025},
volume = {0},
number = {0},
pages = {0--0},
doi = {10.4193/rhin24.528}
}
EUVIMED